10-K Filing

Xenetic Biosciences, Inc. CIK: 1534525 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001683168-21-000969`
Period End Date	20201231
Filing Date	20210316
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	xbio-20201231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 53 Income Statement 32 Cash Flow Statement 62 Stockholders Equity 24

Balance Sheet 53 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	12.50M	shares	Point-in-time
Cash	`Cash`	$11.53M	USD	Point-in-time
Cash	`Cash`	$10.37M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	8.77M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	6.09M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	6.07M	shares	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$722.08K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	8.75M	shares	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$841.96K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$11.09M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.37M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$757.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	-	USD	Point-in-time
Goodwill and indefinite-lived intangible assets	`IndefiniteLivedIntangibleAssetsExcludingGoodwill`	$9.24M	USD	Point-in-time
Goodwill and indefinite-lived intangible assets	`IndefiniteLivedIntangibleAssetsExcludingGoodwill`	$9.24M	USD	Point-in-time
Goodwill and indefinite-lived intangible assets	`IndefiniteLivedIntangibleAssetsExcludingGoodwill`	-	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.21M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$809.99K	USD	Point-in-time
Total assets	`Assets`	$21.55M	USD	Point-in-time
Total assets	`Assets`	$13.18M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$931.13K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$327.40K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$609.53K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$484.03K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$936.93K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.42M	USD	Point-in-time
Deferred tax liability and other long-term liabilities	`DeferredIncomeTaxLiabilitiesNet`	$27.04K	USD	Point-in-time
Deferred tax liability and other long-term liabilities	`DeferredIncomeTaxLiabilitiesNet`	$2.92M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.33M	USD	Point-in-time
Total liabilities	`Liabilities`	$963.97K	USD	Point-in-time
Commitments and contingent liabilities (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingent liabilities (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 and 12,500,000 shares authorized as of December 31, 2020 and December 31, 2019; 8,772,198 and 6,092,432 shares issued as of December 31, 2020 and December 31, 2019, respectively; 8,745,207 and 6,065,441 shares outstanding as of December 31, 2020 and December 31, 2019, respectively	`CommonStockValue`	$8.77K	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 and 12,500,000 shares authorized as of December 31, 2020 and December 31, 2019; 8,772,198 and 6,092,432 shares issued as of December 31, 2020 and December 31, 2019, respectively; 8,745,207 and 6,065,441 shares outstanding as of December 31, 2020 and December 31, 2019, respectively	`CommonStockValue`	$6.09K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$188.24M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$194.13M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-166.01M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-176.90M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.91M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.22M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$17.21M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$21.55M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$13.18M	USD	Point-in-time

Income Statement 32 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`Revenues`	$436.94K	USD	Annual
Total revenues	`Revenues`	$17.07K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.73M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$4.89M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.73M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.40M	USD	Annual
Asset impairment charges (Note 7)	`AssetImpairmentCharges`	$3.28M	USD	Annual
Asset impairment charges (Note 7)	`AssetImpairmentCharges`	$9.24M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$14.37M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$12.90M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-13.94M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-12.89M	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$3.31K	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-492.00	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$126.17K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$108.49K	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$111.80K	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$125.68K	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet`	$-12.78M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet`	$-13.81M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-2.92M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	Annual
Net loss	`NetIncomeLoss`	$-12.78M	USD	Annual
Net loss	`NetIncomeLoss`	$-10.89M	USD	Annual
Deemed dividend	`PreferredStockDividendsIncomeStatementImpact`	$5.28M	USD	Annual
Deemed dividend	`PreferredStockDividendsIncomeStatementImpact`	-	USD	Annual
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-10.89M	USD	Annual
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-18.06M	USD	Annual
Basic and diluted loss per share	`EarningsPerShareBasicAndDiluted`	$-6.33	USD	Annual
Basic and diluted loss per share	`EarningsPerShareBasicAndDiluted`	$-1.70	USD	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.85M	shares	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.39M	shares	Annual

Cash Flow Statement 62 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-12.78M	USD	Annual
Net loss	`NetIncomeLoss`	$-10.89M	USD	Annual
Acquired in-process research and development	`AcquiredInprocessResearchAndDevelopment`	-	USD	Annual
Acquired in-process research and development	`AcquiredInprocessResearchAndDevelopment`	$3.03M	USD	Annual
Asset impairment charges	`AssetImpairmentCharges`	$3.28M	USD	Annual
Asset impairment charges	`AssetImpairmentCharges`	$9.24M	USD	Annual
Deferred income taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$2.92M	USD	Annual
Deferred income taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	-	USD	Annual
Depreciation	`Depreciation`	$757.00	USD	Annual
Depreciation	`Depreciation`	$4.20K	USD	Annual
Amortization of right of use asset	`OperatingLeasePayments`	$28.08K	USD	Annual
Amortization of right of use asset	`OperatingLeasePayments`	$23.29K	USD	Annual
Gain on sale of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$2.00K	USD	Annual
Gain on sale of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	Annual
Gain on settlement with vendor	`GainsLossesOnExtinguishmentOfDebt`	$143.64K	USD	Annual
Gain on settlement with vendor	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Share-based expense	`ShareBasedCompensation`	$806.09K	USD	Annual
Share-based expense	`ShareBasedCompensation`	$468.91K	USD	Annual
Issuance of warrants in connection with reverse stock split	`IssuanceOfWarrantsInConnectionWithReverseStockSplit`	-	USD	Annual
Issuance of warrants in connection with reverse stock split	`IssuanceOfWarrantsInConnectionWithReverseStockSplit`	$63.54K	USD	Annual
Vendor share-based payments	`VendorShareBasedPayments`	$47.43K	USD	Annual
Vendor share-based payments	`VendorShareBasedPayments`	-	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$653.56K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-325.66K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-378.11K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-227.96K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.27M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.40M	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$2.00K	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	-	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$2.00K	USD	Annual
Net proceeds from issuance of common stock in registered direct offering	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Net proceeds from issuance of common stock in registered direct offering	`ProceedsFromIssuanceOfCommonStock`	$5.43M	USD	Annual
Net proceeds from issuance of common stock and warrants in public offering	`ProceedsFromIssuanceOrSaleOfEquity`	-	USD	Annual
Net proceeds from issuance of common stock and warrants in public offering	`ProceedsFromIssuanceOrSaleOfEquity`	$13.42M	USD	Annual
Net proceeds from issuance of common stock and warrants in registered direct offering	`ProceedsFromIssuanceOrSaleOfEquity2`	$2.70M	USD	Annual
Net proceeds from issuance of common stock and warrants in registered direct offering	`ProceedsFromIssuanceOrSaleOfEquity2`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$6.21K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.43M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$16.13M	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$1.16M	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$9.73M	USD	Annual
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$638.12K	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.37M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$638.12K	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.37M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	$8.00	USD	Annual
Right of use assets obtained in exchange for lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$43.33K	USD	Annual
Right of use assets obtained in exchange for lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$70.56K	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	$1.00	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	$7.00	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	$3.03M	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	-	USD	Annual
Issuance of common stock to adjust for Reverse Stock Split	`IssuanceOfCommonStockToAdjustForReverseStockSplit`	-	USD	Annual
Issuance of common stock to adjust for Reverse Stock Split	`IssuanceOfCommonStockToAdjustForReverseStockSplit`	$1.00	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$229.00	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$2.20K	USD	Annual

Stockholders Equity 24 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$9.91M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$17.21M	USD	Point-in-time
Issuance of common stock in December 2020 registered direct offering, net of issuance costs, value	`StockIssuedDuringPeriodValueNewIssues`	$5.43M	USD	Annual
Issuance of common stock and warrants in registered direct offering, net of issuance costs, value	`IssuanceOfCommonStockAndWarrantsInMarch2019RegisteredDirectOfferingNetOfIssuanceCostsValue`	$2.70M	USD	Annual
Issuance of common stock and warrants in July 2019 public offering, net of issuance costs, value	`IssuanceOfCommonStockAndWarrantsInPublicOfferingNetOfIssuanceCostsValue`	$13.42M	USD	Annual
Issuance of common stock in connection with purchase of in-process research and development, value	`IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopmentValue`	$3.03M	USD	Annual
Exercise of pre-funded warrants, value	`ExerciseOfPrefundedWarrantsValue`	$6.21K	USD	Annual
Exercise of purchase warrants, value	`ExerciseOfPurchaseWarrantsValue`	-	USD	Annual
Exercise of purchase warrants, value	`ExerciseOfPurchaseWarrantsValue`	-	USD	Annual
Issuance of common stock to vendor, value	`StockIssuedDuringPeriodValueIssuedForServices`	-	USD	Annual
Issuance of common stock to vendor, value	`StockIssuedDuringPeriodValueIssuedForServices`	-	USD	Annual
Issuance of warrants in connection with reverse stock split, value	`IssuanceOfWarrantsInConnectionWithReverseStockSplitValue`	$63.54K	USD	Annual
Issuance of common stock to adjust for reverse split rounding, value	`StockIssuedDuringPeriodValueOther`	-	USD	Annual
Deemed dividend related to Series B Preferred Stock down round provision	`DeemedDividendRelatedToSeriesBPreferredStockDownRoundProvision`	$5.28M	USD	Annual
Accretion of deemed dividend related to Series B Preferred Stock down round provision	`OtherPreferredStockDividendsAndAdjustments`	$5.28M	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$806.09K	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$468.91K	USD	Annual
Common stock awards to vendors	`AdjustmentsToAdditionalPaidInCapitalOther`	$47.43K	USD	Annual
Net loss	`NetIncomeLoss`	$-12.78M	USD	Annual
Net loss	`NetIncomeLoss`	$-10.89M	USD	Annual
Ending balance, value	`StockholdersEquity`	$9.91M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$17.21M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.